Is it time for a retinoic acid-eluting stent or retinoic acid-coated balloon? Insights from experimental studies of systemic and local delivery of retinoids
Copyright © 2023 Hellenic Society of Cardiology. Published by Elsevier Inc. All rights reserved..
Although the incidence of restenosis and stent thrombosis has substantially declined during the last decades, they still constitute the two major causes of stent failure. These complications are partially attributed to the currently used cytostatic drugs, which can cause local inflammation, delay or prevent re-endothelialization and essentially cause arterial cell toxicity. Retinoic acid (RA), a vitamin A (retinol) derivative, is a naturally occurring substance used for the treatment of cell proliferation disorders. The agent has pleiotropic effects on vascular smooth muscle cells and macrophages: it influences the proliferation, migration, and transition of smooth muscle cells to other cell types and modulates macrophage activation. These observations are supported by accumulated evidence from in vitro and in vivo experiments. In addition, systemic and topical administration of RA can decrease the development of atherosclerotic plaques and reduce or inhibit restenosis after vascular injury (caused by embolectomy, balloon catheters, or ligation of arteries) in various experimental models. Recently, an RA-drug eluting stent (DES) has been tested in an animal model. In this review, we explore the effects of RA in atherosclerosis and the potential of the local delivery of RA through an RA-DES or RA-coated balloon for targeted therapeutic percutaneous vascular interventions. Despite promising published results, further experimental study is warranted to examine the safety and efficacy of RA-eluting devices in vascular artery disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese - 76(2024) vom: 15. März, Seite 75-87 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Samara, Ioanna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5688UTC01R |
|---|
| Anmerkungen: |
Date Completed 12.03.2024 Date Revised 12.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.hjc.2023.08.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360670725 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360670725 | ||
| 003 | DE-627 | ||
| 005 | 20240312233149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.hjc.2023.08.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM360670725 | ||
| 035 | |a (NLM)37567563 | ||
| 035 | |a (PII)S1109-9666(23)00140-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Samara, Ioanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is it time for a retinoic acid-eluting stent or retinoic acid-coated balloon? Insights from experimental studies of systemic and local delivery of retinoids |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2024 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Hellenic Society of Cardiology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Although the incidence of restenosis and stent thrombosis has substantially declined during the last decades, they still constitute the two major causes of stent failure. These complications are partially attributed to the currently used cytostatic drugs, which can cause local inflammation, delay or prevent re-endothelialization and essentially cause arterial cell toxicity. Retinoic acid (RA), a vitamin A (retinol) derivative, is a naturally occurring substance used for the treatment of cell proliferation disorders. The agent has pleiotropic effects on vascular smooth muscle cells and macrophages: it influences the proliferation, migration, and transition of smooth muscle cells to other cell types and modulates macrophage activation. These observations are supported by accumulated evidence from in vitro and in vivo experiments. In addition, systemic and topical administration of RA can decrease the development of atherosclerotic plaques and reduce or inhibit restenosis after vascular injury (caused by embolectomy, balloon catheters, or ligation of arteries) in various experimental models. Recently, an RA-drug eluting stent (DES) has been tested in an animal model. In this review, we explore the effects of RA in atherosclerosis and the potential of the local delivery of RA through an RA-DES or RA-coated balloon for targeted therapeutic percutaneous vascular interventions. Despite promising published results, further experimental study is warranted to examine the safety and efficacy of RA-eluting devices in vascular artery disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a Drug eluting stents | |
| 650 | 4 | |a Restenosis | |
| 650 | 4 | |a Retinoic acid | |
| 650 | 4 | |a Thrombosis | |
| 650 | 7 | |a Retinoids |2 NLM | |
| 650 | 7 | |a Tretinoin |2 NLM | |
| 650 | 7 | |a 5688UTC01R |2 NLM | |
| 650 | 7 | |a Cardiovascular Agents |2 NLM | |
| 700 | 1 | |a Moulas, Anargyros N |e verfasserin |4 aut | |
| 700 | 1 | |a Karanasiou, Georgia |e verfasserin |4 aut | |
| 700 | 1 | |a Papadimitropoulou, Triantafyllia |e verfasserin |4 aut | |
| 700 | 1 | |a Fotiadis, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Michalis, Lampros K |e verfasserin |4 aut | |
| 700 | 1 | |a Katsouras, Christos S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese |d 2005 |g 76(2024) vom: 15. März, Seite 75-87 |w (DE-627)NLM154585718 |x 2241-5955 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2024 |g day:15 |g month:03 |g pages:75-87 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.hjc.2023.08.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2024 |b 15 |c 03 |h 75-87 | ||